Back to search

Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.

Data up to Jan 2025

Published1994
Citations221
References19

Total Citations Per Year

Abstract

References (19)

Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction

1987 • 64,270 citations

Nonparametric Estimation from Incomplete Observations

1992 • 45,923 citations

Promotion of microtubule assembly in vitro by taxol

1979 • 3,521 citations

Taxol stabilizes microtubules in mouse fibroblast cells.

1980 • 1,942 citations

A DISTRIBUTION-FREE k-SAMPLE TEST AGAINST ORDERED ALTERNATIVES

1954 • 1,455 citations

THE IMPACT OF NATIONAL CANCER ACT

1991 • 809 citations

Phase I clinical and pharmacokinetic study of taxol.

1987 • 449 citations

Use of the polymerase chain reaction in the quantitation of MDR-1 gene expression

1990 • 427 citations

Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.

1987 • 286 citations

Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines

1993 • 272 citations

Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.

1993 • 244 citations

The importance of dose intensity in the outcome of chemotherapy.

1988 • 236 citations

Phase I and pharmacodynamic study of taxol in refractory acute leukemias.

1989 • 196 citations

P‐glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines

1991 • 177 citations

High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial.

1987 • 112 citations

Phase I trial of taxol given as a 3-hour infusion every 21 days.

1986 • 96 citations

Taxol administered as a 120 hour infusion

1992 • 48 citations

Current dosage and schedule issues in the development of paclitaxel (Taxol).

1993 • 46 citations

Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer.

1993 • 43 citations

Cited By (0)

No citing papers found in database

Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase… (1994) – Journal of Clinical Oncology | Metascience Observatory Explorer